Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
NCT00338650
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1000
Enrollment
INDUSTRY
Sponsor class
Conditions
Crohn's Disease
Interventions
DRUG:
adalimumab
Sponsor
Abbott